Overview

The Transformation of Locally Advanced Pancreatic Cancer.

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy (paclitaxel (albumin binding) combined with gemcitabine and cisplatin) in the treatment of locally advanced pancreatic cancer in patients with locally advanced pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University
Treatments:
Paclitaxel